InMed Pharmaceuticals Inc. - FORM S-1 - EX-23.1 - CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - July 12, 2021

Attached files

file filename
S-1 - REGISTRATION STATEMENT - InMed Pharmaceuticals Inc.ea144036-s1_inmedpharma.htm
EX-10.7 - AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, DATED MARCH 1, 2021, BETWEE - InMed Pharmaceuticals Inc.ea144036ex10-7_inmedpha.htm
EX-10.6 - AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, DATED MARCH 1, 2021, BETWEE - InMed Pharmaceuticals Inc.ea144036ex10-6_inmedpha.htm
EX-10.5 - AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, DATED MARCH 1, 2021, BETWEE - InMed Pharmaceuticals Inc.ea144036ex10-5_inmedpha.htm
EX-10.4 - AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, DATED MARCH 1, 2021, BETWEE - InMed Pharmaceuticals Inc.ea144036ex10-4_inmedpha.htm
EX-10.3 - AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, DATED MARCH 1, 2021, BETWEE - InMed Pharmaceuticals Inc.ea144036ex10-3_inmedpha.htm
EX-5.1 - OPINION OF NORTON ROSE FULBRIGHT CANADA LLP - InMed Pharmaceuticals Inc.ea144036ex5-1_inmedpha.htm
EX-4.3 - FORM OF SPECIFIC COMMON SHARE CERTIFICATE - InMed Pharmaceuticals Inc.ea144036ex4-3_inmedpha.htm

Exhibit 23.1

 

 

 

KPMG LLP

PO Box 10426 777 Dunsmuir Street

Vancouver BC V7Y 1K3

Canada

Telephone (604) 691-3000

Fax (604) 691-3031

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

InMed Pharmaceuticals Inc.:

 

We consent to the use of our report dated September 8, 2020, with respect to the consolidated financial statements of InMed Pharmaceuticals Inc. included herein and to the reference to our firm under the heading “Experts” in the prospectus.

 

/s/ KPMG LLP  

 

Chartered Professional Accountants

 

Vancouver, Canada

July 12, 2021

 

© 2021 KPMG LLP, an Ontario limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

 

 

InMed Pharmaceuticals Inc. Reports